Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2008-05-27
2008-05-27
Salimi, Ali R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C424S204100
Reexamination Certificate
active
07378099
ABSTRACT:
The present invention provides immunogenic and pharmaceutical compositions for the treatment and prevention of human papillomavirus (HPV)-associated cancers and in particular, cervical cancer. In particular, this invention relates to fusion proteins, and the nucleic acids encoding these fusion proteins, used to generate immune responses against HPV. Specifically, this invention provides for fusions of HPV E6 and E7 in which the E6 and/or E7 contains one or more mutations. These mutations abrogate the transformation activity of these oncogenic proteins and, thus, confer safety to the E6/E7 fusions. In addition, these fusions maintain or increase the immunogenic efficacy of E6 and E7. Any gene or protein delivery method can be used to deliver or package the immunogenic compositions of the present invention.
REFERENCES:
patent: 5719054 (1998-02-01), Boursnell et al.
patent: 6004557 (1999-12-01), Edwards et al.
patent: 6306397 (2001-10-01), Edwards et al.
patent: 6365160 (2002-04-01), Webb et al.
patent: 6726912 (2004-04-01), Webb et al.
patent: WO 99/10375 (1999-03-01), None
Von Knebel Doeberitz, M., et al., Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 anti-sense RNA, (1992) Int J Cancer 51, 831-4.
Crook, T., et al., Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras, (1989) Embo J 8, 513-9.
He, Y., et al., Growth inhibition of Human Papillomavirus 16 DNA-positive Mouse Tumor by Antisense RNA Transcribed from U6 Promoter, (1997) Cancer Res 57, 3993-9.
Smotkin, D., et al., Transcription of human papillomavirus type 16 early genes in a cervical cancer and a cancer-derived cell line and identification of the E7 protein, (1986) Proc Natl Acad Sci U S A B3, 4680-4.
Durst, M., et al., Human Papillomavirus Type 16 (HPV 16) Gene Expression and DNA Replication in Cervical Neoplasia: Analysis by In Situ Hybridization, (1992) Virology 189, 132-40.
Dyson, N., et al., The Human Papilloma Virus-16 E7 Oncoprotein is Able to Bind to the Retinoblastoma Gene Product, (1989) Science 243, 934-7.
Cobrink, D., et al., The Retinoblastoma protein and the regulation of cell cycling, (1992) Trends Biochem Sci 17, 312-5.
Scheffner, M., et al., The E6 Oncoprotein Encoded by Human Papillomavirus Types 16 and 18 Promotes the Degradation of p53, (1990) Cell 63, 1129-36.
Nakagawa, M., et al., Cytotoxic T Lymphocyte Responses to E6 and E7 Proteins of Human Papillomavirus Type 16: Relationship to Cervical Intraepithelial Neoplasia, (1997) J Infect Dis 175, 927-31.
Kadish, A. S., et al., Lymphoproliferative Responses to Human Papillomavirus (HPV) Type 16 Proteins E6 and E7: Outcome of HPV Infection and Associated Neoplasia, (1997) J Natl Cancer Inst 89, 1285-93.
Feltkamp, M. C., et al., Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors, (1995) Eur J Immunol 25, 2638-42.
Lin, K. Y., et al., Treatment of Established Tumors with a Novel Vaccine That Enhances Major Histocompatibility Class II Presentation of Tumor Antigen, (1996) Cancer Res 56, 21-6.
Horton, R. M., et al., Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension, (1989) Gene 77, 61-8.
Pushko, P., et al., Replicon-Helper Systems from Attenuated Venezuelan Equine Encephalitis Virus: Expression of Heterologous Genes in Vitro and Immunization against Heterologous Pathogenes In Vivo, (1997) Virology 239, 389-401.
Dalal, S., et al., Mutational Analysis of Human Papillomavirus Type 16 E6 Demonstrates that p53 Degradation Is Necessary for Immortalization of Mammary Epithelial Cells, (1996) J Virol 70, 683-8.
Shi, W., et al., Human Papillomavirus Type 16 E7 DNA Vaccine: Mutation In the Open Reading Frame of E7 Enhances Specific Cytotoxic T-Lymphocyte Induction and Anitumor Activity, (1999) J Virol 73, 7877-81.
Gao, Q., et al., Human Papillomavirus Type 16 E6-Induced Degradation of E6TP1 Correlates with Its Ability to Immortalize Human Mammary Epithelial Cells, (2001) J Virol 75, 4459-66.
Edmonds, C., et al., A Point Mutational Analysis of Human Papillomavirus Type 16 E7 Protein, (1989) J Virol 63, 2650-6.
Ressing, M. E., et al., Human CTL Epitopes Encoded by Human Papillomavirus Type 16 E6 and E7 Identified Through In Vivo and In Vitro Immunogenicity Studies of HLA-A*0201-Binding Peptides, (1995) J Immunol 154, 5934-43.
Ressing, M. E., et al., Occasional Memory Cytotoxic T-Cell Responses of Patients with Human Papillomavirus Type 16-positive Cervical Lesions against a Human Leukocyte Antigen-A*0201-restricted E7-encoded Epitope, (1996) Cancer Res 56, 582-8.
Evans, E. M., et al., Infitration of Cervical Cancer Tissue with Human Papillomavirus-specific Cytotoxic T-Lymphocytes, (1997) Cancer Res 57, 2943-50.
Rammensee, H. G., et al., Peptides Naturally Presented by MHC Class I Molecules, (1993) Annu Rev Immunol 11, 213-44.
Velders, M. P., et al., Eradication of Established Tumors by Vaccination with Venezuelan Equine Encephalitis Virus Replicon Particles Delivering Human Papillomavirus 16 E7 RNA, (2001) Cancer Res 61, 7861-7.
Boursnell, M.E.G, et al., Construction and characterization of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer, (1996) Vaccine 14, 1485-1494.
Borysiewicz, L.K., et al., A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer, (1996) The Lancet 347, 1523-27.
Gao, Q., et al., The E6 Oncoproteins of High-Risk Papillomavirus Bind to a Novel Putative GAP Protein, E6TP1, and Target It for Degradation, (1999) Mol. and Cell. Biol. 19, 733-744.
De Jong, A., et al., Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine, (20020 Vaccine 20, 3456-3464.
Daemen, T., et al., Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7, (2002) Gene Therapy 9, 85-94.
Fields Virology (2001) Fourth Edition, Ch. 65 and 66, pp. 2197-2264 Knipe & Howley Eds., Lippincott Williams and Wilkins.
Eiben GL et al., Establishment of an HLA-A*0201 Human Papillomavirus Type 16 Tumor Model to Determine the Efficacy of Vaccination Strategies in HLA-A0201 Transgenic Mice, Cancer Research, Oct. 15, 2002 vol. 62, No. 20 p. 5792-5799.
Engelhard, V. H., et al., Influenza A-Specific, HLA-A2.1-Restricted Cytotoxic T Lymphocytes From HLA-A2.1 Transgenic Mice Recognize Fragments of the M1 Protein, (1991) J Immunol 146, 1226-1232.
Shirai et al., CTL Responses of HLA-A2.1-Transgenic Mice Specific for Hepatitis C Viral Peptides Predict Epitopes for CTL of Humans Carrying HLA-A2.1, (1995) J Immunol 154, 2733-2742.
Zur Hausen, H., Papillomaviruses and Cancer: From Basic Studies to Clinical Application. Nat. Rev. Cancer, 2:342-350, 2002.
Walboomers, J. M., et al., Human Papillomavirus is a Necessary Cause of Invasive Cervical Cancer Worldwide, J. Pathol., 189:12-19, 1999.
Munger, K., et al., Biological Activities and Molecular Targets of the Human Papillomavirus E7 Oncoprotein, Oncogene, 20:7888-7898, 2001.
Wallin, K. L., et al., Type-Specific Persistence of Human Papillomavirus DNA Before the Development of Invasive Cervical Cancer. N. Eng. J. Med., 341:1633-1638, 1999.
Mantovanni, F., et al., The Human Papillomavirus E6 Protein and its Contribution to Malignant Progression. Oncogene, 20:7874-7887, 2001.
Eiben, G.L., et al., The Cell-Mediated Immune Response to Human Papillomavirus-Induced Cervical Cancer: Implications for Immunotherapy. Adv. Can. Res., 86:113-148, 2002.
Rayner, J. O., et al., Alphavirus Vectors and Vaccination. Rev. Med. Virol., 12:279-296, 2002.
Griffin, D. E., et al., Regulators of Apoptosis on the Road to Persistent Alphavirus Infection. Annu. Rev. Microbiol., 51:565-592, 1997.
Feltkamp, M. C. W., et al., Vaccination with Cytotoxic T Lymphocyte
Cassetti Maria Cristina
McElhiney Susan P.
Pullen Jeffrey K.
Smith Larry
Moran Michael J.
Salimi Ali R.
Wyeth
LandOfFree
Human papillomavirus polypeptides and immunogenic compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human papillomavirus polypeptides and immunogenic compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human papillomavirus polypeptides and immunogenic compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2788920